PLK 1‐activating IFI 16– STING – TBK 1 pathway induces apoptosis of intestinal epithelial cells in patients with intestinal Behçet's syndrome
The FEBS Journal · 2024
DOI: 10.1111/febs.17147 ↗At a glance
Journal article in The FEBS Journal, 2024. Written by Hua-Fang Bao and 12 co-authors. Institution: Department of Rheumatology and Immunology, Huadong Hospital, Fudan University, Shanghai, China. Major MEDLINE topics: Behcet Syndrome, Polo-Like Kinase 1, Protein Serine-Threonine Kinases, Apoptosis. Cited 8 times so far (Crossref); 48 references. Funded by: National Natural Science Foundation of China, Technical Standards Project of the Science and Technology Commission of Shanghai Municipality.
Abstract (original language)
Inflammatory signals from immunological cells may cause damage to intestinal epithelial cells (IECs), resulting in intestinal inflammation and tissue impairment. Interferon‐γ‐inducible protein 16 (IFI16) was reported to be involved in the pathogenesis of Behçet's syndrome (BS). This study aimed to investigate how inflammatory cytokines released by immunological cells and IFI16 participate in the pathogenesis of intestinal BS. RNA sequencing and real‐time quantitative PCR (qPCR) showed that the positive regulation of tumor necrosis factor‐α (TNF‐α) production in peripheral blood mononuclear cells (PBMCs) of intestinal BS patients may be related to the upregulation of polo like kinase 1 (PLK1) in PBMCs ( P = 0.012). The plasma TNF‐α protein level in intestinal BS was significantly higher than in healthy controls (HCs; P = 0.009). PBMCs of intestinal BS patients and HCs were co‐cultured with human normal IECs (NCM460) to explore the interaction between immunological cells and IECs. Using IFI16 knockdown, PBMC‐NCM460 co‐culture, TNF‐α neutralizing monoclonal antibody (mAb), stimulator of interferon genes (STING) agonist 2′3′‐cGAMP, and the PLK1 inhibitor SBE 13 HCL, we found that PLK1 promotes the secretion of TNF‐α from PBMCs of intestinal BS patients, which causes overexpression of IFI16 and induces apoptosis of IECs via the STING–TBK1 pathway. The expressions of IFI16, TNF‐α, cleaved caspase 3, phosphorylated STING (pSTING) and phosphorylated tank binding kinase 1 (pTBK1) in the intestinal ulcer tissue of BS patients were significantly higher than that of HCs (all P < 0.05). PLK1 in PBMCs of intestinal BS patients increased TNF‐α secretion, inducing IEC apoptosis via activation of the IFI16–STING–TBK1 pathway. PLK1 and the IFI16–STING–TBK1 pathway may be new therapeutic targets for intestinal BS.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Rheumatology and Immunology, Huadong Hospital, Fudan University, Shanghai, China.
- Department of Gastrointestinal Endoscopy, Huadong Hospital, Fudan University, Shanghai, China.
ORCID profiles: Jian-Long Guan
Funding
- National Natural Science Foundation of China
- Technical Standards Project of the Science and Technology Commission of Shanghai Municipality
Cite
APA
Bao, H. F., She, C. H., Hou, C. C., Ji, D. N., Hu, D., Zou, J., Shen, Y., Jian, L. L., Cai, J. F., Ye, J. F., Luo, D., Ma, H. F., & Guan, J. L. (2024). PLK 1‐activating IFI 16– STING – TBK 1 pathway induces apoptosis of intestinal epithelial cells in patients with intestinal Behçet's syndrome. The FEBS Journal. https://doi.org/10.1111/febs.17147
Vancouver
Bao HF, She CH, Hou CC, Ji DN, Hu D, Zou J, et al. PLK 1‐activating IFI 16– STING – TBK 1 pathway induces apoptosis of intestinal epithelial cells in patients with intestinal Behçet's syndrome. The FEBS Journal. 2024. doi:10.1111/febs.17147
BibTeX
@article{Bao2024,
author = {Bao, Hua-Fang and She, Chun-Hui and Hou, Cheng-Cheng and Ji, Da-Nian and Hu, Dan and Zou, Jun and Shen, Yan and Jian, Lei-Lei and Cai, Jian-Fei and Ye, Jing-Fen and Luo, Dan and Ma, Hai-Fen and Guan, Jian-Long},
title = {PLK 1‐activating IFI 16– STING – TBK 1 pathway induces apoptosis of intestinal epithelial cells in patients with intestinal Behçet's syndrome},
journal = {The FEBS Journal},
year = {2024},
doi = {10.1111/febs.17147}
}
EUVIMED